Pulmonx Corporation
NASDAQ:LUNGMedical - Devices
+$0.05 today
- Market cap
- $117.15M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$1.27
Volume 0.48M
Average 0.44M
LUNG Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Pulmonx CorporationNASDAQ: LUNG
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $4.54M fell 26.7% year over year, behind the -6.5% change in trailing-twelve-month cost of revenue. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +19.2% a year.
Context
- Cost of revenue amounted to 25.8% of revenue in FY2025, down 0.2 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -26.7% toward the trailing-twelve-month pace of -6.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 23.36M USD
- Year-over-year change
- +7.2%
- 4-year CAGR
- +16.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.36M | +7.2% |
| FY2024 | 2024-12-31 | 21.79M | +21.6% |
| FY2023 | 2023-12-31 | 17.92M | +29.9% |
| FY2022 | 2022-12-31 | 13.8M | +7.9% |
| FY2021 | 2021-12-31 | 12.79M | — |
Cost of Revenue vs competitors
How LUNG compares with its peers on the latest reported figures
- LUNG's LTM Mar 2026 cost of revenue of $21.7M is the 3rd highest of the 10 companies compared; the peer median is $66K.
- Its year-over-year change of -6.5% is the 4th highest of 7, against a peer median of -22.8%.
- Cost of revenue amounts to 24.5% of revenue for LUNG, versus a peer median of 32.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $56.89M | +26.1% | +51.7% | 55.7% | |
| LTM Jun 2026 | $25.72M | +4.4% | +21.7% | 32.2% | |
| LTM Mar 2026 | $21.7M | -6.5% | +19.2% | 24.5% | |
| LTM Mar 2026 | $7.48M | +18.5% | +4.9% | 48.8% | |
| LTM Mar 2026 | $693K | — | — | 7.6% | |
| LTM Mar 2026 | $66K | -82.3% | — | — | |
| LTM Mar 2026 | $33K | -50.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$228K | -137.1% | — | — |
| Peer median (excluding LUNG) | $66K | -22.8% | +21.7% | 32.2% | |
Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.42M | 53.66M | 68.68M | 83.79M | 90.5M |
| Cost of Revenue | 12.79M | 13.8M | 17.92M | 21.79M | 23.36M |
| Gross Profit | 35.63M | 39.87M | 50.75M | 62M | 67.14M |
| Gross Margin | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| Research & Development | 13.06M | 15.4M | 18.08M | 17.57M | 19.49M |
| Selling, General & Admin | 69.87M | 83.11M | 94.61M | 102.14M | 101.31M |
| Operating Expenses | 82.93M | 98.5M | 112.69M | 119.71M | 120.8M |
| Depreciation & Amortization | 867K | 1.51M | 1.95M | 1.59M | 1.05M |
| EBITDA | (46.62M) | (55.99M) | (55.09M) | (50.79M) | (49.17M) |
| EBITDA Margin | -96.3% | -104.3% | -80.2% | -60.6% | -54.3% |
| Operating Income | (47.3M) | (58.64M) | (61.94M) | (57.7M) | (53.66M) |
| Operating Margin | -97.7% | -109.3% | -90.2% | -68.9% | -59.3% |
| Interest Income | 400K | 1.53M | 5.57M | 5.06M | 2.65M |
| Interest Expense | 829K | 1.07M | 3.23M | 3.51M | 3.16M |
| Other Income / Expenses | (1.01M) | 67K | 1.66M | 1.81M | 286K |
| Income Before Tax | (48.32M) | (58.57M) | (60.27M) | (55.89M) | (53.38M) |
| Pre-Tax Margin | -99.8% | -109.1% | -87.8% | -66.7% | -59.0% |
| Income Tax Expense | 343K | 353K | 571K | 500K | 626K |
| Net Income | (48.66M) | (58.92M) | (60.84M) | (56.39M) | (54M) |
| Net Margin | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| EPS (Basic) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| EPS (Diluted) | (1.35) | (1.59) | (1.60) | (1.44) | (1.33) |
| Weighted Avg Shares | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
| Weighted Avg Shares (Diluted) | 36.13M | 37.1M | 37.97M | 39.11M | 40.69M |
Pulmonx Corporation
NASDAQ:LUNG
Intrinsic Alpha fair value
Locked
Current Price
$2.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.